Another anecdote of the bursting ebulience for Biotechs. As Valeant collapses further, Kura Oncology - which IPO'd yesterday at $8 - has today crashed back below its IPO price (down over 56% from yesterday's opening highs).
Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the pricing of its public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share.
